Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07659769

Global Healthcare Study on Hidradenitis Suppurativa

The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hidradenitis Suppurativa (HS) Bacterial Infections Bacterial Infections and Mycoses Hidradenitis Hidradenitis Suppurativa Hidradenitis Suppurativa (Acne Inversa) Infections Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Age range

14 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed General Consent Form, or equivalent document
  • Confirmed diagnosis of Hidradenitis Suppurativa

Exclusion criteria

  • Inability to provide informed consent.
  • Datasets with ambiguous or unclear diagnosis.

Treatment and study plan

Primary outcomes

  1. International Hidradenitis Suppurativa Severity Score System (IHS4)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed measure of hidradenitis suppurativa severity based on the number of inflammatory nodules, abscesses, and draining tunnels; higher scores indicate more severe disease.

Secondary outcomes

  1. Hurley Staging System

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed classification of hidradenitis suppurativa severity categorized as Stage I, Stage II, or Stage III.

  2. Sartorius Hidradenitis Suppurativa Severity Score (HSS)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed measure of hidradenitis suppurativa severity incorporating lesion counts and anatomical involvement; higher scores indicate more severe disease.

  3. Physician Global Assessment (PGA)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Clinician-assessed global measure of hidradenitis suppurativa severity on a scale from 0 to 4, with higher scores indicating more severe disease.

  4. Dermatology Life Quality Index (DLQI)

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.

  5. Patient-reported Numerical Rating Scale (NRS) for severity of hidradenitis suppurativa

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported assessment of overall hidradenitis suppurativa severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).

  6. Patient-reported Numerical Rating Scale (NRS) for pain related to hidradenitis suppurativa

    Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.

    Patient-reported assessment of hidradenitis suppurativa-related pain on a numerical rating scale from 0 (no pain) to 10 (worst imaginable pain).

Study contacts

Contact information is provided by the study sponsor or research team.

Johannes Didaskalu

CONTACT

[email protected]

Julia-Tatjana Maul, Prof. Dr. med.

CONTACT

[email protected]

+41 76 441 51 09

Sponsors and collaborators

Lead sponsor

Julia Tatjana Maul

Other

Collaborators

  • University Hospital, Zürich
  • University of Zurich

Registry information

Acronym: GHSHS

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Jun 22, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.